Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma

Daratumumab (DARA) is an FDA-approved high-affinity monoclonal antibody targeting CD38 that has shown promising therapeutic efficacy in double refractory multiple myeloma (MM) patients. Despite the well-established clinical efficacy of DARA, not all heavily pretreated patients respond to single-agen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Nicholas, Ko, Sooah, Shokeen, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487729/
https://www.ncbi.nlm.nih.gov/pubmed/34611478
http://dx.doi.org/10.18632/oncotarget.28074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487729/
https://www.ncbi.nlm.nih.gov/pubmed/34611478
http://dx.doi.org/10.18632/oncotarget.28074

Ejemplares similares